June 18-22, 2019 Lugano
136-P | One-year real-life targeted next generation sequencing for lymphoma diagnosis: study of patients from the French Lymphoma Network in Rhne-Alpes | Cme Bommier | Received |
137-P | MUTATIONAL LANDSCAPE OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT DIAGNOSIS AND AT PROGRESSION ASSESSED BY CIRCULATING TUMOR DNA ANALYSIS | Alfredo Rivas-Delgado | Received |
138-P | Targeted genotyping of circulating tumor DNA for classical Hodgkin Lymphoma monitoring: a prospective study | Vincent Camus | Received |
139-P | Analysis of Circulating Tumor DNA (ctDNA) in Cerebrospinal Fluid Detects the Presence of Central Nervous System (CNS) Involvement in B-Cell Lymphomas | Sabela Bobillo | Received |
140-P | Molecular analyses and an innovative diagnostic algorithm in MYC-negative Burkitt-like lymphoma with 11q aberration: a single institution experience | Grzegorz Rymkiewicz | Received |
141-P | High risk of adverse events after autologous stem-cell transplantation in lymphoma patients with DNA repair pathway mutations: A nation-wide cohort study | Simon Husby | Received |
144-P | Personalized prediction in DLBCL enabled by functional mouse genomics | Clemens A. Schmitt | Received |
146-P | Population-Based Outcomes in Large B-cell lymphoma by WHO Subtype: Findings from the UKs Haematological Malignancy Research Network | Russell Patmore | Received |
147-P | Refinement of MUM1 expression threshold for Double Positive CD10 MUM1 Diffuse Large B Cell Lymphoma allows a better Cell of Origin Classification for GCB subtype | Celine Bossard | Received |
148-P | Reduced BCL2 expression suggests alternative survival mechanisms in HIV() Diffuse Large B Cell Lymphoma (DLBCL) of Germinal Center Origin | Alanna Maguire | Received |
149-P | Single cell level analysis of MYC/ BCL2/ BCL6 co-expression in Diffuse large B-cell lymphoma through multiplexed quantitative immunofluorescence | Michelle Poon | Received |
150-P | Clinical significance of T-cell exhaustion in patients with diffuse large B-cell lymphoma | Sirpa Leppa | Received |
151-P | The influence of tumor immune microenvironment and tumor immunity on the pathogenesis, treatment and prognosis of post-transplant lymphoproliferative disorders (PTLD) | Saito Hideaki | Received |
152-P | JAK-STAT pathway and epigenetic regulators are critical players in BI-ALCL pathogenesis ? | Camille Laurent | Received |
153-P | Chromosome 20 loss is characteristic for Breast-implant Associated Anaplastic Large Cell Lymphoma | Bauke Ylstra | Received |
154-P | Whole Genome Sequencing Reveals Potential Therapeutic Strategy for MEITL | Dachuan Huang | Received |
155-P | Whole-genome sequencing reveals immunotherapeutic options for Natural-killer/T cell lymphoma patients. | Jing Quan Lim | Received |
156-P | KIR3DL2 Mutation may Define a High Rate of Response of AITL to Tipifarnib | antonio gualberto | Received |
158-P | A PTCL gene signature capturing stromal and neoplastic data stratifies PTCL/NOS and AITL into different groups with variable survival probability | Marta Rodriguez | Received |
159-P | Multicentric MFI30 study: standardization of CD30 expression by flow cytometry in Non-Hodgkin lymphoma. | Lucile BASEGGIO | Received |
160-P | Survival continues to increase in chronic lymphocytic leukemia: a population-based analysis among 20,324 patients diagnosed in the Netherlands between 1989 and 2015 | Lina van der Straten | Received |
161-P | Proteomics markers prognostic for outcome of chronic lymphocytic leukemia patients under treatment: results from the HOVON-109 study | Lina van der Straten | Received |
164-P | Hypertension (HTN) in Patients (Pts) treated with Ibrutinib (Ibr) for Chronic Lymphocytic Leukemia (CLL) | MARYAM SARRAF YAZDY | Received |
165-P | An improved benefit-risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received 2 or more prior therapies | Ian Flinn | Received |
166-P | Effect of dose modifications on response to duvelisib in patients with relapsed/refractory CLL/SLL in the DUO trial | Paolo Ghia | Received |
167-P | Patterns of duvelisib-induced lymphocytosis in patients with R/R CLL or SLL including those with high-risk factors treated in the DUO trial | Jacqueline Barrientos | Received |
168-P | Brief co-administration of idelalisib may improve the long-term efficacy of frontline chemoimmunotherapy in chronic lymphocytic leukaemia: 3-year follow-up from the RIAltO trial | Andrew Pettitt | Received |
170-P | Long term follow up of FoRT: A Phase 3 Multi-Center Prospective Randomized Trial of Radiation Therapy for Follicular and Marginal Zone Lymphoma | Amy Kirkwood | Received |
171-P | Systemic therapy after Radiation Therapy in stage I-II follicular lymphoma: Final results of an International Randomized Trial TROG 99.03 | Michael MacManus | Received |
172-P | Results of a Multicenter Phase2 Trial of Involved Field Radiotherapy Alone for Localized Non-Gastric Marginal Zone Lymphoma: TROG 05.02 | Michael MacManus | Received |
173-P | Outcomes of 180 Patients with Indolent Lymphomas Treated with Very Low Dose (4 Gy) Radiation Therapy Alone | Karen Chau | Received |
175-P | FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY | Simone Ferrero | Received |
176-P | Rituximab alone (R) versus rituximab plus bendamustine (BR) for splenic (SMZL) and nodal marginal zone lymphoma (NMZL). | Adam Olszewski | Received |
180-P | Outcomes after early transformation (tPOD24) vs. early follicular lymphoma progression (fPOD24) in follicular lymphoma treated with frontline immunochemotherapy | Matthew Maurer | Received |
182-P | WhiMSICAL (Waldenstrms Macroglobulinemia Study Involving CArt-wheeL): A Global Patient-derived Data Registry Mapping Treatment and Quality of Life. | Ibrahim Tohidi-Esfahani | Received |
184-P | Clinico-biological characteristics and treatment outcomes for Agressive Mantle Cell Lymphoma patients included in clinical trials. A LYSA study. | Mathieu Baldacini | Received |
186-P | Evolution of clonal hematopoiesis in mantle cell lymphoma patients before, during, and after induction chemotherapy and autologous stem cell transplantation | Simon Husby | Received |
188-P | Early progression of mantle cell lymphoma depicts a high-risk disease with poor response to subsequent therapies and a dismal outcome | Christian Winther Eskelund | Received |
189-P | The efficacy of ibrutinib in patients with relapsed mantle cell lymphoma after first line intensive chemo-immunotherapy and ASCT a retrospective study from the LWP-EBMT | Claire Burney | Received |
190-P | IBRUTINIB COMPARED TO STANDARD CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RECURRENCE OF MANTLE CELL LYMPHOMA | Chiara Rusconi | Received |
192-P | The Clinical Course of Diffuse Large B-cell Lymphoma (DLBCL) over Time: A Multistate Survival Analysis Using Meta-Data From 13 First-line Randomized Trials | a&287;lar a&287;layan | Received |
193-P | Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): an individual patient-level analysis across international trial | Norbert Schmitz | Received |
194-P | The Elderly Project by the Fondazione Italiana Linfomi: a Prospective Comprehensive Geriatric Assessment (CGA) of 1353 Elderly Patients with Diffuse Large B-Cell Lymphoma | Michele Spina | Received |
196-P | Clinical Characteristics and Outcomes of Stage I Diffuse Large B Cell Lymphoma (DLBCL) in the Rituximab-Era | Sabela Bobillo | Received |
197-P | Population-based study on different regimens of R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma in the Netherlands supports the use of 6 cycles of R-CHOP21 | Djamila Issa | Received |
198-P | PET-DRIVEN RADIOTHERAPY IN PATIENTS WITH LOW RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): THE DLCL10 MULTICENTER PHASE 2 TRIAL BY FONDAZIONE ITALIANA LINFOMI (FIL) | Monica Balzarotti | Received |
199-P | SAFETY ANALYSIS OF AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP NHL29: A PHASE II STUDY OF IBRUTINIB, RITUXIMAB AND MINI-CHOP IN VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED DLBCL | Emma Verner | Received |
200-P | Prospective multicenter registry for secondary CNS involvement in malignant lymphoma: an update with data from 181 patients | Felicitas Lammer | Received |
203-P | Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Preliminary results of the R2-GDP-GOTEL Trial | Luis de la Cruz Merino | Received |
204-P | MSKCC Early Experience Using Radiotherapy as a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma Before CD19 CAR T Therapy | Brandon Imber | Received |
205-P | Highly Favorable Outcomes with Salvage RT Followed by ASCT in Relapsed & Refractory DLBCL Patients Refractory to Salvage Chemotherapy | Joanna Yang | Received |
206-P | Post-transplant Lymphoproliferative Disorder in Patients with Lymphoma after Allogeneic Hematopoietic Stem Cell Transplantation | Ayumi Fujimoto | Received |
207-P | Depth of remission following first line HP-eradication is an independent prognostic factor in gastric MALT lymphoma | Markus Raderer | Received |
208-P | 90Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT lymphoma) The Zeno Study | Marangon Miriam | Received |
209-P | Transformed mucosa-associated lymphoid tissue lymphomas: A single institution retrospective study including PCR-based clonality analysis | Barbara Kiesewetter | Received |
210-P | Incidence and Treatment Outcomes of Patients with Transformed Marginal Zone Lymphoma Treated with RCHOP-Like Regimens | Sridevi Rajeeve | Received |
211-P | Allogeneic hematopoietic stem cell transplantation for primary mediastinal large B-cell lymphoma patients relapsing after high dose chemotherapy with autologous stem cell transplantation: Data from the Japan Society for Hematopoietic Cell Transplantation | Eisei Kondo | Received |
212-P | PROGNOSTIC FACTORS (PFs) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL) TREATED WITH RITUXIMAB-CHOP (RCHOP) RADIOTHERAPY (RT) | Theodoros Vassilakopoulos | Received |
213-P | Is it radiotherapy necessary for primary mediastinal B-cell lymphoma (PMBL) patients achieving PET negativity after immunochemotherapy? | Marie Trnkova | Received |
214-P | PD-1 Inhibitor plus Chemotherapy in Relapsed/refractory Primary Mediastinal Large B-cell Lymphoma (PMLBCL) with Aggressive Bulky Disease | Qian Mei | Received |
215-P | Temozolomide in relapse/refractory primary vitreo-retinal lymphoma (R/R PVRL): a simple, cheap, effective and well tolerated treatment. Result of the largest study on R/R PVRL, from the LOC network | Sylvain Choquet | Received |
216-P | Clinical features, treatment and outcome of Neurolymphomatosis: Single Institution experienceTitle | Mattia Novo | Received |
217-P | Bicentric pilot study on age-adapted high-dose chemotherapy and autologous stem cell transplant in newly diagnosed primary CNS lymphoma patients 65 years - MARiTA trial | Elisabeth Schorb | Received |
219-P | PD-1 blockade in a French series of 13 relapsed / refractory NK/T-cell lymphoma patients | Lucile Couronné | Received |
220-P | A prospective phase II study of pegaspargase-COEP plus radiotherapy in patients with newly diagnosed extra-nodal NK/T-cell lymphoma | Shaoxuan Hu | Received |
222-P | CLINICAL OUTCOMES AND DIAGNOSIS-TO-TREATMENT INTERVAL IN PATIENTS WITH NK/T-CELL LYMPHOMA: 7-YEAR FOLLOW-UP OF THE NKEA STUDY | Motoko Yamaguchi | Received |
223-P | Clinicopathological differences of nodal PTCL with Tfh phenotype from AITL and PTCL, NOS, and detection of prognostic marker of nodal PTCL with Tfh phenotype | Takaharu Suzuki | Received |
224-P | EVENT FREE SURVIVAL AT 12 MONTHS AND 24 MONTHS AS PREDICTORS FOR OUTCOME OF SYSTEMIC PERIPHERAL T CELL LYMPHOMA: ANALYSIS OF NATIONWIDE THAI LYMPHOMA STUDY GROUP | Kitsada Wudhikarn | Received |
225-P | Bone Marrow Involvement, but No Blood Involvement, Impairs Survival in Angioimmunoblastic T cell Lymphoma: An Ancillary Study of the REVAIL Trial | Francois Lemonnier | Received |
227-P | Phase I/II Study of CHOEP Plus Lenalidomide As Initial Therapy for Patients with Stage II-IV Peripheral T-Cell Lymphoma: Phase II Results | Matthew Lunning | Received |
229-P | Anaplastic Large Cell Lymphoma, ALK-Negative: analysis of 235 Cases collected by the T-Cell Project. | monica civallero | Received |
230-P | Increased Risk of Second Primary Hematologic and Solid Malignancies in Patients with Mycosis Fungoides: Impact on Overall Survival in SEER Registry | Aleksandr Lazaryan | Received |
233-P | CLINICAL AND BIOLOGICAL PREDICTORS OF OUTCOME IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA: A SINGLE CENTER EXPERIENCE OF 205 PATIENTS. | Gregorio Barilà | Received |
234-P | Clinical characteristics and outcome of patients with Hodgkins lymphoma older than 60 years treated in Switzerland over the last 17 years | Stefanie Aeppli | Received |
236-P | DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA (HD): RESULTS OF A PHASE II, PROSPECTIVE STUDY BY FONDAZIONE ITALIANA LINFOMI | Rita Mazza | Received |
238-P | PET-adapted nivolumab /- ICE as initial salvage therapy in relapsed/refractory Hodgkin lymphoma | Alex Herrera | Received |
239-P | Transcriptional networks associated with treatment failure in advanced-stage Hodgkin lymphoma: data from the RATHL trial (CRUK/07/033) | Sean Lim | Received |
241-P | First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of FIL ONLUS | Stefoni Vittorio | Received |
243-P | CHECKPOINT INHIBITION BEFORE HAPLOIDENTICAL TRANSPLATATION IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA PATIENTS IS ASSOCIATED WITH HIGHER PFS WITHOUT INCREASED TOXICITIES | chiara de philippis | Received |
244-P | How to donor, stem cell source, and conditioning regimen for haploidentical transplants with post-transplant cyclophosphamide for lymphoma: a report of the EBMT LWP | Ali Bazarbachi | Received |
246-P | REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE PROGRAM | Catherine Thieblemont | Received |
247-P | Safety and Preliminary Efficacy in Patients With Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in TRANSCEND NHL 001 | Maria Wering | Received |
249-P | Safety and Efficacy of Axicabtagene Ciloleucel (axi-cel) in Older Patients: Results from The US Lymphoma CAR-T Consortium | Dahlia Sano | Received |
251-P | Phase 1 Study of AntiCD19 CAR-T Cells with TNFa Transmembrane Domain and 41BB, CD3zeta Costimulatory Domains. Responses in Subjects with Rapidly Progressive Lymphoma | Paolo Caimi | Received |
252-P | CD19/CD20-redirected bispecific CAR T cell treatment in patients with relapsed or refractory B-cell Non-Hodgkin lymphoma | Yao Wang | Received |
256-P | Clinical Implications of Cytopenias Beyond Day 30 after Axi-cel Therapy in Patients with Relapsed/Refractory Large B-cell Lymphoma | Paolo Strati | Received |
257-P | Comprehensive report of anti-CD19 chimeric antigen receptor T-cells (CAR-T) associated Non Relapse Mortality (CART-NRM) from FAERS | Kartik Anand | Received |
258-P | Safety of Allogeneic Hematopoietic Cell Transplant in Adults after CD19 Targeted Chimeric Antigen Receptor-modified T-cell (CAR-T) Therapy | Mazyar Shadman | Received |
259-P | Title: Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202) | Ahmed Sawas | Received |
260-P | Ipilimumab plus Lenalidomide for Treatment of Relapsed Disease after Allogeneic Stem Cell Transplantation (AlloSCT) in Patients (pts) with Lymphoid Malignancies | Issa Khouri | Received |
261-P | Donor lymphocyte infusions induce durable responses in patients with follicular, mantle and T cell lymphomas relapsing after an alloSCT. An EBMT-LWP Study. | Stephen Robinson | Received |
267-P | Reversal of immune tolerance and increased survival after XPO1 and BTK inhibition in mouse models of primary CNS lymphoma (PCNSL) | Isabel Jiménez | Received |
269-P | The novel bispecific CD47-CD19 antibody TG-1801 potentiates the activity of ublituximab-umbralisib (U2) drug combination in preclinical models of B-NHL | emmanuel normant | Received |
271-P | Preliminary results of a Phase 1 dose escalation study of the first-in-class anti-CD74 antibody drug conjugate (ADC), STRO-001, in advanced B-cell malignancies. | Shannon Matheny | Received |
272-P | Long-term outcome of patients with relapsed/refractory B-cell non- Hodgkin lymphoma treated with bispecific antibody blinatumomab in a phase I trial | Vera Dufner | Received |
273-P | A first-in-human trial of the novel multi-action therapy tinostamustine (EDO-S101) in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) | Gillian Wain | Received |
277-P | Safety and efficacy of venetoclax combined with rituximab, ifosfamide, carboplatin and etoposide (VICER) for treatment of relapsed DLBCL: Final results from the Phase 1 Trial | Paolo Caimi | Received |
278-P | Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Jean-Marie Michot | Received |
279-P | Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL) and follicular lymphoma (FL) | David Sermer | Received |
280-P | Safety and efficacy of atezolizumab, obinutuzumab and venetoclax combination for relapsed/refractory non-Hodgkin lymphomas: Results from the safety-run of a LYSA study | Charles Herbaux | Received |
281-P | Phase 1B Study of ViPOR (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Analysis of Safety and Efficacy | Christopher Melani | Received |
285-P | Title: Improvement of Rituximab administration by premedication with rupatadine, montelukast and their combination | rouslan Kotchetkov | Received |
June 18-22, 2019 Lugano
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|